GLPG1690

GLP1690 is a potent inhibitor of autotaxin (Ki = 15 nM). It inhibits the production of lysophosphatidic acid (LPA) in mouse, rat, and human plasma (IC50s = 418, 542, and 242 nM, respectively). GLPG1690 (30 mg/kg) reduces extracellular matrix deposition in the lung as well as LPA 18:2 levels in bronchoalveolar lavage fluid in a mouse model of pulmonary fibrosis induced by bleomycin (Cay-13877).Formal Name: 2-[[2-ethyl-6-[4-[2-(3-hydroxy-1-azetidinyl)-2-oxoethyl]-1-piperazinyl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)-5-thiazolecarbonitrile. CAS Number: 1628260-79-6. Synonyms: Ziritaxestat. Molecular Formula: C30H33FN8O2S. Formula Weight: 588.7. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: 80 mg/ml. lambdamax: 252 nm. SMILES: O=C(N1CC(O)C1)CN2CCN(C3=CN4C(C(C)=C3)=NC(CC)=C4N(C5=NC(C6=CC=C(F)C=C6)=C(C#N)S5)C)CC2. InChi Code: InChI=1S/C30H33FN8O2S/c1-4-24-29(35(3)30-34-27(25(14-32)42-30)20-5-7-21(31)8-6-20)39-15-22(13-19(2)28(39)33-24)37-11-9-36(10-12-37)18-26(41)38-16-23(40)17-38/h5-8,13,15,23,40H,4,9-12,16-18H2,1-3H3. InChi Key: REQQVBGILUTQNN-UHFFFAOYSA-N.